Evidence map›Paper›PMID 40212202›Full record

ReviewAnnals of medicine and surgery (2012)2025

Exploring the potential of CAR-NK cell therapy in the management of head and neck cancer (HNC): a narrative review.

Erfan Zare, Seyed MohammadHossein Mostafavi, Naeim Norouzi, Amirhossein Larijani, Seyedeh Mohadese Mosavi Mirkalaie, Seyyed Amin FallahMortezaNejad, Maryam Jafari, Erfan Shahabinejad, Masome Aghaei Lasboo, Saeid Anvari

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Annals of medicine and surgery (2012), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Erfan ZareCancer Immunology and Immunotherapy Research Center, Ardabil University of Medical Sciences, Ardabil, Iran.
Seyed MohammadHossein MostafaviStudent Research Committee, School of Medicine, Guilan University of Medical Sciences, Rasht, Iran.
Naeim NorouziRegenerative Medicine, Organ Procurement and Transplantation Multi Disciplinary Center, Razi Hospital, School of Medicine, Guilan University Of Medical Sciences, Rasht, Iran.
Amirhossein LarijaniRegenerative Medicine, Organ Procurement and Transplantation Multi Disciplinary Center, Razi Hospital, School of Medicine, Guilan University Of Medical Sciences, Rasht, Iran.
Seyedeh Mohadese Mosavi MirkalaieStudent Research Committee, School of Medicine, Anzali International Campus, Guilan University of Medical Sciences, Rasht, Iran.
Seyyed Amin FallahMortezaNejadStudent Research Committee, School of Medicine, Guilan University of Medical Sciences, Rasht, Iran.
Maryam JafariStudent Research Committee, School of Medicine, Anzali International Campus, Guilan University of Medical Sciences, Rasht, Iran.
Erfan ShahabinejadStudent Research Committee, Rafsanjan University of Medical Sciences, Rafsanjan, Iran.
Masome Aghaei LasbooDepartment of Internal Medicine, Guilan University of Medical Sciences, Rasht, Iran.
Saeid AnvariRegenerative Medicine, Organ Procurement and Transplantation Multi Disciplinary Center, Razi Hospital, School of Medicine, Guilan University Of Medical Sciences, Rasht, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The management of head and neck squamous cell carcinoma (HNSCC) presents significant challenges due to the complex anatomy of the region and potential functional impairments caused by conventional treatments. Recent advancements in immunotherapy, particularly CAR-NK cell therapy, provide a possible option by using the innate immune system to target tumor cells. Methods: This review focuses on the therapeutic potential of CAR-NK cell potential for head and neck cancer, covering its mechanisms, challenges, and future directions. Results: CAR-NK cell therapy presents an innovative approach with fewer side effects compared to traditional immunotherapies. Targeting specific receptors such as PD-L1, EGFR, CD44v6, and MUC1 enhances tumor cell elimination while minimizing off-target effects. Pre-clinical and early clinical results are promising, pointing toward a possible role in personalized therapeutic options. Conclusions: CAR-NK cells offer a novel therapeutic avenue for HNSCC by combining targeted cytotoxicity with improved safety profiles. Further research and clinical trials are imperative to optimize this approach, paving the way for advanced, patient-specific treatments.

Indexed as

CAR-NK cellschimeric antigen receptorshead and neck cancerimmunotherapynatural killer cell

Identifiers

PMID40212202
PMCPMC11981392

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.